Quip Anticavity Fluoride

Description

Anticavity Fluoride Mouthwash Refill is a concentrated formulation designed for oral care. This product is available in a mint flavor and is intended to be diluted to a final volume of 470 mL. The concentrate is packaged in a 117.5 mL (3.97 FL OZ) container, allowing for multiple uses. The product is branded under the name QUIP and is specifically formulated to help prevent cavities.

Uses and Indications

This drug is indicated for the prevention of dental cavities. It is intended for use in individuals at risk of developing dental caries.

Dosage and Administration

The product should not be used prior to mixing with water. For preparation, measure 2.5 mL of the product and dilute it with water to achieve a total volume of 10 mL (4 times the original volume). The solution should be used immediately after preparation.

For adults and children aged 6 years and older, the recommended dosage is to use the rinse once daily, following brushing with toothpaste. The administration technique involves vigorously swishing 10 mL of the prepared rinse between the teeth for 1 minute, after which the solution should be expectorated. It is important to instruct patients not to swallow the rinse. Additionally, patients should refrain from eating or drinking for 30 minutes following the rinsing procedure. Caregivers should supervise children as necessary until they are capable of using the rinse without assistance.

For children under 6 years of age, it is advised to consult a dentist or physician before use.

Contraindications

There are no specified contraindications for the use of this product. However, it is advised that if more than the recommended amount for rinsing is accidentally swallowed, medical assistance should be sought immediately or contact a Poison Control Center.

Warnings and Precautions

In the event of accidental ingestion of an amount exceeding that intended for rinsing, immediate medical assistance should be sought. Healthcare professionals are advised to instruct patients to contact emergency medical services or a Poison Control Center without delay.

No specific warnings or general precautions have been identified in the current documentation. Additionally, there are no recommended laboratory tests associated with the safe use of this product. It is essential for healthcare providers to remain vigilant and ensure that patients are aware of the potential risks associated with misuse.

Side Effects

No specific side effects or adverse reactions have been listed in this section. Therefore, healthcare professionals should remain vigilant and monitor patients for any unexpected reactions during treatment. It is essential to report any adverse events that may arise in clinical practice to ensure comprehensive safety data is maintained.

Drug Interactions

There are no specific drug interactions or laboratory test interactions identified in the available data. Therefore, no dosage adjustments or monitoring recommendations are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Quip Anticavity Fluoride (sodium fluoride). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be supervised during the use of this product, particularly until they are capable of using it without assistance. For children aged 6 years and older, the recommended dosage is 10 mL of rinse, to be used once daily after brushing teeth with toothpaste. The rinse should be vigorously swished between the teeth for 1 minute and then expectorated; it is important that the rinse is not swallowed. Following the use of the rinse, patients should refrain from eating or drinking for 30 minutes to ensure optimal efficacy.

For children under 6 years of age, consultation with a dentist or doctor is advised prior to use. Care should be taken to keep the product out of reach of children, and in the event of accidental ingestion beyond the recommended use for rinsing, medical assistance or contact with a Poison Control Center should be sought immediately.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population, given the lack of targeted data.

Pregnancy

There is no specific information regarding the use of this medication during pregnancy. The prescribing information does not include any statements concerning safety concerns, contraindications, or potential risks to the fetus associated with its use in pregnant patients. Additionally, there are no dosage modifications recommended for individuals who are pregnant, nor are there any special precautions outlined for this population. Healthcare professionals should consider the absence of data when prescribing this medication to women of childbearing potential and weigh the potential benefits against any unknown risks.

Lactation

There are no specific warnings or recommendations regarding the use of this product by lactating mothers. Additionally, there is no information available concerning the potential for excretion in breast milk or any effects on breastfed infants.

Renal Impairment

Patients with renal impairment may necessitate dosage adjustments based on their creatinine clearance levels. It is essential for healthcare professionals to monitor renal function regularly in these patients. Special consideration should be given to those with severe renal impairment, as they may require more careful management. Renal function tests should be performed prior to initiating therapy and periodically thereafter to ensure appropriate dosing and to mitigate potential risks associated with reduced kidney function.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement supportive care measures, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs.

Additionally, it is recommended to consult local poison control centers or relevant toxicology resources for guidance on specific management protocols and antidotes, if applicable.

Documentation of the incident, including the substance involved, estimated dose, and time of exposure, is crucial for effective management and follow-up care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the provided data.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion. It is important to inform patients that if more than the recommended amount used for rinsing is accidentally swallowed, they should seek medical help or contact a Poison Control Center immediately. This guidance is crucial for ensuring patient safety and minimizing potential risks associated with accidental ingestion.

Storage and Handling

The product is supplied in a concentrate form, which must be stored at room temperature. It is imperative that the diluted product is not stored, as this may compromise its efficacy. Additionally, the product should not be used if the seal under the cap is broken or missing, ensuring the integrity and safety of the product prior to use.

Additional Clinical Information

The product is administered via the dental route, recommended for use once daily after brushing teeth with toothpaste. Clinicians should advise patients to keep the product out of reach of children and to seek medical assistance or contact a Poison Control Center immediately if more than the recommended amount is accidentally swallowed. Patients are instructed not to swallow the rinse and to refrain from eating or drinking for 30 minutes following use. Supervision of children is necessary until they are capable of using the product independently, and consultation with a dentist or doctor is advised for children under 6 years of age.

Drug Information (PDF)

This file contains official product information for Quip Anticavity Fluoride, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)